Background:
Peritoneal dialysis is an essential renal replacement therapy for patients with end-stage renal disease (ESRD), particularly in those regions with limited access to hemodialysis. The study aimed to assess the long-term outcomes of continuous ambulatory peritoneal dialysis (CAPD) among ESRD patients mainly residing in the rural sectors.
Methods:
A total of 62 patients with ESRD (76% male, 68% aged 18–59 years) on CAPD were assessed. Clinical data included rates of peritonitis, technique survival, and clearance studies, which were monitored over a follow-up period of 2670 patient-months. Patients were classified as having either short-term (<2.5 years) or long-term (>2.5 years) follow-up.
Results:
The rate of peritonitis was 1 episode per 133.5 patient-months, and no patient developed exit-site infections. The overall patient survival rates were 77%, 67%, and 48% at 1, 2, and 3 years, respectively, with median survival of 36 months. The residual renal function was directly correlated with the total Kt/V urea, while serum albumin levels showed corresponding correlation with protein intake and loss. The transport of peritoneal solute was classified into four groups: low, low-average, high-average, and high transport, which implied that the dialysis efficiency is different in those groups.
Conclusion:
CAPD is a valid and viable RRT for ESRD patients in the rural and remote areas. Given good patient selection, proper training, and strict adherence to aseptic techniques, CAPD offers favorable survival outcomes. This study supports the broader introduction of CAPD in resource-limited settings, especially in developing countries.
Keywords: Peritoneal Dialysis, End-Stage Renal Disease, Continuous Ambulatory Peritoneal Dialysis, Rural Healthcare, Survival Outcomes, Peritonitis
How to cite this article: Devi S, Acharya A, Routray RK, Dash C, Gaude RP., A Prospective Observational Case Study of Chronic Glomerulonephritis and End-Stage Renal Disease Patients on Continuous Ambulatory Peritoneal Dialysis. Int J Drug Deliv Technol. 2026;16(3): 234-240; DOI: 10.25258/ijddt.16.3.29
Source of support: Nil.
Conflict of interest: None